Cross-study hierarchical modeling of stratified clinical trial data.

Hierarchical random-effects models can be used to estimate treatment or other covariate effects in single-study analyses coordinated over multiple clinical units and can also be extended to a wide variety of cross-study applications. After reviewing the single-study case, we use data from five trial protocols to look for units that tend to have treatment effects consistently above or below the study-specific grand mean across several studies. As a first step, we summarize the patient-level data as study-specific and unit-specific estimated treatment effects and standard errors using independent Cox regression models. We then compare the results of a hierarchical model using these data summaries as input to those produced by a more fully Bayesian method that uses the actual patient-level survival data. We also compare various different models using a deviance information criterion, a recent extension of the Akaike information criterion designed for hierarchical models. Our procedure appears to be effective at answering the question whether certain clinical units of the Terry Beirn Community Programs for Clinical Research on AIDS are better than others at identifying treatment effects where they exist.

[1]  A E Gelfand,et al.  Approaches for optimal sequential decision analysis in clinical trials. , 1998, Biometrics.

[2]  D J Sargent,et al.  A general framework for random effects survival analysis in the Cox proportional hazards setting. , 1998, Biometrics.

[3]  J. Neaton,et al.  A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The New England journal of medicine.

[4]  R. Littell SAS System for Mixed Models , 1996 .

[5]  J P Matts,et al.  Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The Journal of infectious diseases.

[6]  Adrian F. M. Smith,et al.  Sampling-Based Approaches to Calculating Marginal Densities , 1990 .

[7]  T. Louis,et al.  A randomized, placebo‐controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV‐infected individuals , 1998 .

[8]  W. El-Sadr,et al.  Weekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection , 1997, Annals of Internal Medicine.

[9]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .

[10]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[11]  K. Larntz,et al.  Data analysis issues for protocols with overlapping enrollment. , 1996, Statistics in medicine.

[12]  Bradley P. Carlin,et al.  BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..

[13]  Thomas A. Louis,et al.  Meta-Analysis for Explanation: A Casebook. , 1992 .

[14]  G. Casella,et al.  Explaining the Gibbs Sampler , 1992 .

[15]  B. Carlin,et al.  Hierarchical Proportional Hazards Regression Models for Highly Stratified Data , 1999, Biometrics.

[16]  Purushottam W. Laud,et al.  Predictive Model Selection , 1995 .

[17]  K Abrams,et al.  Approximate Bayesian inference for random effects meta-analysis. , 1998, Statistics in medicine.

[18]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[19]  Alan E. Gelfand,et al.  Model choice: A minimum posterior predictive loss approach , 1998, AISTATS.

[20]  D K Stangl,et al.  Prediction and decision making using Bayesian hierarchical models. , 1995, Statistics in medicine.

[21]  W. Gilks,et al.  Adaptive Rejection Sampling for Gibbs Sampling , 1992 .

[22]  B P Carlin,et al.  Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[23]  D J Spiegelhalter,et al.  Comparison of Bayesian with group sequential methods for monitoring clinical trials. , 1989, Controlled clinical trials.

[24]  David J. Spiegelhalter,et al.  Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.

[25]  D A Berry,et al.  A case for Bayesianism in clinical trials. , 1993, Statistics in medicine.

[26]  Jianming Ye On Measuring and Correcting the Effects of Data Mining and Model Selection , 1998 .

[27]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[28]  J Hornberger,et al.  The cost-benefit of a randomized trial to a health care organization. , 1998, Controlled clinical trials.

[29]  C. Pettinelli,et al.  Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter , 1996 .

[30]  David S. Cordray,et al.  Meta-Analysis for Explanation , 1994 .

[31]  M D Hughes,et al.  Evaluating surrogate markers. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.